Skip To Main Content
Lilly
Menu closed
Lilly
    Lilly

    You are now leaving the LillyMedical website

    The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
    Click "Continue" to proceed or "Return" to return to LillyMedical.

    Diabetes Journal Publications

    This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

    If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979). For our publication linking statement click here.

    For all other requests, please visit our Contact Lilly services.

    Basaglar® (insulin glargine)

    Full Prescribing Information

    A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects.
    Published Date: December 1, 2021

    No Publication Journals

    Efficacy and safety of LY2963016 in Chinese T1DM patients previous treated with Lantus
    Published Date: April 26, 2022
    Immunogenicity of LY2963016 insulin glargine and Lantus insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
    Published Date: February 20, 2022
    Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial
    Published Date: June 13, 2021

    Safety and Efficacy of Biosimilar Insulin Glargine (Basaglar) in Indian Patients with Type 2 Diabetes Mellitus: Results from a Multicenter, Open-Label, Single-Arm, Phase 4 Trial (ABEX)
    Published Date: February 1, 2025
    Real-World Patterns of Basal Insulin Use with Other Diabetes Medications Among People with Type 2 Diabetes Between 2014 and 2020.
    Published Date: May 15, 2023
    Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning.
    Published Date: May 11, 2023
    Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009─2020
    Published Date: April 17, 2023
    Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen.
    Published Date: February 16, 2023
    Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study.
    Published Date: September 2, 2022
    Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018.
    Published Date: July 5, 2021
    Evaluating the relationship between clinical and demographic characteristics of insulin-using people with diabetes and their health outcomes: a cluster analysis application.
    Published Date: July 5, 2021

    Humalog

    Humalog® U-100 (insulin lispro injection) | Full Prescribing Information
    Humalog® U-200 (insulin lispro injection) | Full Prescribing Information
    Humalog® MIX50/50™ (50% insulin lispro protamine suspension 50% insulin lispro injection [rDNA origin]) | Full Prescribing Information
    Humalog® MIX75/25™ (75% insulin lispro protamine suspension 25% insulin lispro injection [rDNA origin]) | Full Prescribing Information

    No Publication Journals

    No Publication Journals

    No Publication Journals

    The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes.
    Published Date: May 15, 2023
    Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning.
    Published Date: May 11, 2023
    Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen.
    Published Date: February 16, 2023
    Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study.
    Published Date: September 2, 2022
    Predicting Response to Bolus Insulin Therapy in Patients With Type 2 Diabetes.
    Published Date: May 20, 2022
    Multinational observational study to understand insulin treatment intensification: Japanese subgroup analysis of the MOSAIc study
    Published Date: January 6, 2022
    An estimation model for postprandial blood glucose levels in patients with type 2 diabetes mellitus
    Published Date: July 26, 2021
    Missed and mistimed insulin doses in people with diabetes: a systematic literature review
    Published Date: July 16, 2021
    Evaluating the relationship between clinical and demographic characteristics of insulin-using people with diabetes and their health outcomes: a cluster analysis application.
    Published Date: July 8, 2021
    Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018.
    Published Date: July 5, 2021

    Humulin

    Humulin® R (U-100) (regular insulin human injection, USP [rDNA origin]) | Full Prescribing Information
    Humulin® R (U-500) (regular U-500 [concentrated] insulin human injection, USP [rDNA origin]) | Full Prescribing Information
    Humulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin]) | Full Prescribing Information
    Humulin® N U-100 (human insulin [rDNA origin] isophane suspension) | Full Prescribing Information

    Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements.
    Published Date: February 1, 2022

    No Publication Journals

    The Effect of Prestudy Insulin Therapy on Safety and Efficacy of Human Regular U-500 Insulin by Pump or Injection: A Posthoc Analysis.
    Published Date: August 1, 2021

    No Publication Journals

    Lyumjev® (insulin lispro - aabc)

    Full Prescribing Information

    Ultra Rapid Lispro (Lyumjev®) Shortens Time to Recovery from Hyperglycaemia Compared to Humalog® in Individuals with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion
    Published Date: October 9, 2023
    Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents, and adults with type 1 diabetes mellitus
    Published Date: May 11, 2023
    An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and Depths.
    Published Date: November 3, 2022
    Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites.
    Published Date: June 14, 2022
    Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
    Published Date: January 25, 2022
    Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study
    Published Date: January 25, 2022

    Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes
    Published Date: September 25, 2023
    Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System.
    Published Date: November 25, 2021
    Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study
    Published Date: October 4, 2021

    Increased Time in Range with Ultra Rapid Lispro Treatment in Participants with Type 2 Diabetes: PRONTO-Time in Range
    Published Date: April 11, 2023
    Efficacy and safety of ultra rapid lispro (URLi) versus Lispro in children and adolescents with type 1 diabetes: PRONTO-Peds
    Published Date: September 9, 2022
    Ultra Rapid Lispro Improves Postprandial Glucose Control Versus Lispro in Combination With Insulin Glargine/Degludec in Adults With Type 2 Diabetes: A Prospective, Randomized, Double-Blind Phase 3 Trial
    Published Date: August 4, 2022
    Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study.
    Published Date: July 4, 2022
    Long-term Efficacy and Safety of Ultra Rapid Lispro in Japanese Patients With Type 1 Diabetes: Subpopulation Analysis of the 52-Week PRONTO-T1D Study.
    Published Date: September 1, 2021
    Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.
    Published Date: June 16, 2021

    The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes.
    Published Date: May 15, 2023
    Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning.
    Published Date: May 11, 2023
    Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009─2020
    Published Date: April 17, 2023
    Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen.
    Published Date: February 16, 2023
    Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study.
    Published Date: September 2, 2022
    Predicting Response to Bolus Insulin Therapy in Patients With Type 2 Diabetes.
    Published Date: May 20, 2022
    Missed and mistimed insulin doses in people with diabetes: a systematic literature review
    Published Date: July 16, 2021
    Evaluating the relationship between clinical and demographic characteristics of insulin-using people with diabetes and their health outcomes: a cluster analysis application.
    Published Date: July 8, 2021
    Trends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018.
    Published Date: July 5, 2021

    Mounjaro® (tirzepatide)

    Full Prescribing Information

    Counterregulatory Response to Hypoglycemia During a Hypoglycemic Clamp in People with Type 2 Diabetes Treated with Tirzepatide
    Published Date: September 2, 2025
    Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.
    Published Date: January 6, 2025
    Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
    Published Date: May 26, 2024
    Improvements in Post-Challenge Lipid Response following Tirzepatide Treatment in Patients with Type 2 Diabetes
    Published Date: November 20, 2023
    A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes.
    Published Date: June 7, 2023
    Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes
    Published Date: March 1, 2023
    Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Published Date: June 8, 2022
    Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
    Published Date: April 27, 2022
    A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
    Published Date: November 19, 2021

    Extent of MASH resolution without worsening of fibrosis across clinically relevant subgroups in the SYNERGY-NASH phase 2 trial
    Published Date: June 6, 2025
    Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
    Published Date: February 24, 2022
    Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects with Type 2 Diabetes
    Published Date: October 5, 2021
    The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis
    Published Date: September 20, 2021

    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
    Published Date: December 18, 2025
    Efficacy and safety of tirzepatide added to basal insulin in Chinese patients with type 2 diabetes (SURPASS-CN-INS): a double-blind, randomized, phase 3 trial
    Published Date: October 30, 2025
    Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled phase 3 trial
    Published Date: September 18, 2025
    Predictors of initial and sustained glycemic and weight response to tirzepatide: a post hoc analysis of SURPASS-4
    Published Date: July 8, 2025
    Insulin sensitivity and beta-cell function following tirzepatide in Japanese patients with type 2 diabetes: a SURPASS J-mono analysis
    Published Date: February 14, 2025
    Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial
    Published Date: February 1, 2025
    Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials
    Published Date: January 12, 2025
    Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials
    Published Date: January 9, 2025
    Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.
    Published Date: August 28, 2024
    Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)
    Published Date: February 7, 2024
    Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
    Published Date: February 4, 2024
    Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
    Published Date: February 1, 2024
    Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4?weeks in the SURPASS-1 monotherapy trial.
    Published Date: October 27, 2023
    Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials
    Published Date: October 18, 2023
    Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-Mono Trial
    Published Date: October 16, 2023
    Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study
    Published Date: October 4, 2023
    Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
    Published Date: October 3, 2023
    Achieving Normoglycemia with Tirzepatide: Analysis of SURPASS 1-4 trials
    Published Date: September 6, 2023
    Tirzepatide in Hispanic/Latino Patients with Type 2 Diabetes: A Subgroup Analysis of the SURPASS program.
    Published Date: August 29, 2023
    Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
    Published Date: August 1, 2023
    Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post-Hoc Analysis
    Published Date: June 2, 2023
    Relationship Between Body Weight Change and Glycemic Control with Tirzepatide Treatment in People with Type 2 Diabetes: A Post Hoc Assessment of the SURPASS Clinical Trial Program
    Published Date: May 31, 2023
    Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
    Published Date: May 25, 2023
    Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients With Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
    Published Date: March 31, 2023
    Systolic Blood Pressure Reduction with Tirzepatide in Patients with Type 2 Diabetes: Insights from SURPASS Clinical Program
    Published Date: March 24, 2023
    Safety and efficacy analyzes across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS program)
    Published Date: December 22, 2022
    Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Published Date: December 13, 2022
    Change of pharmacodynamics parameters following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono sub-study)
    Published Date: October 2, 2022
    Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    Published Date: September 21, 2022
    Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison
    Published Date: May 19, 2022
    Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control captured with continuous glucose monitoring in participants with type 2 diabetes (SURPASS-3 CGM): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
    Published Date: April 23, 2022
    Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
    Published Date: April 22, 2022
    Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Published Date: February 28, 2022
    Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
    Published Date: February 24, 2022
    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Published Date: November 13, 2021
    Once-weekly tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
    Published Date: October 18, 2021
    Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Published Date: August 14, 2021
    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Published Date: August 5, 2021
    Safety and efficacy of once-weekly tirzepatide as add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes mellitus in Japan (SURPASS J-combo): a multi centre, randomised, open label, parallel group phase 3 trial
    Published Date: July 29, 2022
    Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
    Published Date: July 29, 2022
    Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Published Date: July 10, 2021

    Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide: A Randomized Clinical Trial
    Published Date: April 7, 2025
    Understanding the Impact of Non-alcoholic Steatohepatitis with Metabolic Comorbidities on Adults: A Real-World Qualitative Study
    Published Date: February 29, 2024
    An Economic Evaluation of the Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study.
    Published Date: December 1, 2023
    Impact of Weight Change on Glycemic Control and Metabolic Parameters in T2D: A Retrospective US Study Based on Real-World Data
    Published Date: December 1, 2023
    Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States.
    Published Date: November 18, 2023
    The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    Published Date: November 7, 2023
    Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
    Published Date: January 18, 2023
    Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.
    Published Date: May 5, 2022
    Health State Utilities Associated with Weight Loss in Type 2 Diabetes and Obesity
    Published Date: November 4, 2021
    Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data.
    Published Date: September 1, 2021
    Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments.
    Published Date: July 23, 2021

    Trulicity® (dulaglutide)

    Full Prescribing Information

    Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.
    Published Date: November 17, 2021

    No Publication Journals

    A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN)
    Published Date: May 7, 2024
    Practical applications of a nausea and vomiting model in the clinical development of additional doses of dulaglutide
    Published Date: October 18, 2023
    Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
    Published Date: September 21, 2023
    Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.
    Published Date: August 1, 2023
    Biomarker Changes Associated with Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis
    Published Date: March 31, 2023
    General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial
    Published Date: March 10, 2023
    Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
    Published Date: March 7, 2023
    Indicators of Kidney Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease Treated With Dulaglutide
    Published Date: February 8, 2023
    Gender Differences in Cardiovascular Risk, Treatment, and Outcomes: Post hoc Analysis from the REWIND Trial
    Published Date: January 6, 2023
    Glycaemic Efficacy of an Expanded Dose Range of Dulaglutide According to Baseline Glycated Haemoglobin (HbA1c) Subgroup: Post hoc Analysis of AWARD-11
    Published Date: December 1, 2022
    Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
    Published Date: December 1, 2022
    Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-hoc Analysis from the REWIND Randomized Trial
    Published Date: September 9, 2022
    A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.
    Published Date: August 22, 2022
    Once-Weekly Dulaglutide for Treatment of Youth with Type 2 Diabetes
    Published Date: June 4, 2022
    Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
    Published Date: May 11, 2022
    Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study
    Published Date: May 11, 2022
    Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial
    Published Date: April 21, 2022
    Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials
    Published Date: March 9, 2022
    HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis from the REWIND Trial
    Published Date: March 1, 2022
    Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
    Published Date: January 24, 2022
    Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
    Published Date: December 6, 2021
    Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of Incidence and Prevalence in AWARD-11
    Published Date: September 14, 2021
    Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.
    Published Date: August 28, 2021
    Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial
    Published Date: July 29, 2021
    Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
    Published Date: July 9, 2021
    Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.
    Published Date: June 30, 2021
    Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial
    Published Date: June 22, 2021

    The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Resource Use and Costs of Treatment in Clinical Practice in France, Germany, and Italy
    Published Date: July 4, 2024
    An Economic Evaluation of the Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study.
    Published Date: December 1, 2023
    Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study
    Published Date: September 23, 2023
    The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
    Published Date: September 15, 2023
    The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Final, 24-month Analysis of Time to First Significant Treatment Change, Treatment Persistence, and Clinical Outcomes
    Published Date: September 13, 2023
    Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study
    Published Date: September 21, 2022
    The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Disposition, Clinical Characteristics and Treatment Persistence at 12 Months
    Published Date: August 3, 2022
    Are We There Yet? Increasing Use of Cardioprotective Antihyperglycemic Agents in Patients with T2DM and CVD or CV Risk in the US
    Published Date: June 27, 2022
    Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.
    Published Date: May 24, 2022
    Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)
    Published Date: May 18, 2022
    Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials
    Published Date: March 9, 2022
    Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.
    Published Date: March 6, 2022
    Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments.
    Published Date: July 23, 2021
    The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
    Published Date: June 7, 2021

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Consumer Health Privacy Notice
    • Accessibility Statement
    • Sitemap
       

      This site is intended for US Healthcare Professionals only.

      4.0.93 05/2026 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2026. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
      Cookie Settings
      Facebook X LinkedIn
      Lilly